ALA Diagnostics, S.L.

ALA Diagnostics, S.L. is a biotechnological startup revolutionizing Multiple Sclerosis Diagnosis in the Healthcare Market. The company aims to develop and market solutions for the diagnosis of pathologies with high prevalence and/or unmet medical needs. ALA Diagnostics emerged to capitalize on an opportunity to create a diagnostic kit for Multiple Sclerosis, based on a patented recombinant protein. This diagnostic biomarker has already been validated in 598 human samples, positioning it as the only clinically validated specific biomarker for the diagnosis of Multiple Sclerosis in blood. The company's solution is a rapid, simple, inexpensive, non-invasive diagnostic test applicable for early disease diagnosis and easy to integrate into clinical routine. Founded in 2019 and headquartered in Spain, ALA Diagnostics received a significant €1.10M Venture Round investment on 22 June 2023 from BeAble Capital. ALA Diagnostics' pipeline is designed by clinical teams to address deficiencies encountered in their care activities, showcasing a promising future within the Health Care industry.